Your session is about to expire
Dovato vs Juluca
Introduction
For patients living with HIV (Human Immunodeficiency Virus), certain antiretroviral therapies can help manage the viral load and boost the immune system. Dovato and Juluca are two such prescribed medications for this purpose. They each contain different combinations of drugs but both have effects in managing HIV infection. Dovato is a combination of dolutegravir, an integrase strand transfer inhibitor (INSTI), and lamivudine, a nucleoside analogue reverse transcriptase inhibitor (NRTI). It works by blocking enzymes that the virus needs to multiply while also stopping HIV from copying itself, hence reducing its presence in the body. On the other hand, Juluca consists of rilpivirine, which is a non-nucleoside reverse transcriptase inhibitor (NNRTI) along with dolutegravir; these work together to prevent replication of the virus thereby decreasing its impact on one's health.
Dovato vs Juluca Side By Side
| Attribute | Dovato | Juluca |
|---|---|---|
| Brand Name | Dovato | Juluca |
| Contraindications | Previous allergic reactions to any of its components, taking certain medicines like dofetilide, rifampin, St John's wort | Previous allergic reactions to any of its components, taking certain medicines like dofetilide, rifampin, St John's wort |
| Cost | $2,375 for 30 tablets | $3,150 for 30 tablets |
| Generic Name | dolutegravir and lamivudine | dolutegravir and rilpivirine |
| Most Serious Side Effect | Immune system changes (Immune Reconstitution Syndrome), Liver problems, Lactic Acidosis, Allergic reactions, Change in body fat distribution | Signs of an allergic reaction, Severe depression with suicidal thoughts, Unusual changes in behavior or mood swings, Liver issues, Rapid heartbeat or palpitations, Signs of infection |
| Severe Drug Interactions | Dofetilide, rifampin, St John's wort | Dofetilide, rifampin, St John's wort |
| Typical Dose | One tablet once daily | One tablet daily with a meal |
What is Dovato?
Dovato and Juluca are both antiretroviral medications used in the treatment of HIV, marking significant advancements from early options for managing this condition. Dovato is a combination of two drugs: dolutegravir and lamivudine. It was first approved by the FDA in 2019 as a complete regimen for treating HIV-1 infection in adults with no prior antiretroviral therapy history. This medication works by blocking the virus's ability to replicate, thus reducing its presence within an individual's system.
Juluca, on the other hand, combines dolutegravir with rilpivirine and received FDA approval earlier than Dovato, in 2017. Like Dovato, it inhibits viral replication but requires that the patient be virologically suppressed on a stable antiretroviral regimen before initiating treatment.
Both medications have been developed to minimize side effects associated with older classes of HIV treatments; however they still carry potential side effects including headaches and diarrhea. Importantly though, neither drug has a major influence on other physiological processes beyond their targeted action against HIV-1.
What conditions is Dovato approved to treat?
Dovato is approved for the treatment of different HIV-1 infections:
- New, previously untreated HIV-1 infection in adults
- Replacing the current antiretroviral regimen in individuals who are virologically suppressed on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to either dolutegravir or lamivudine.
How does Dovato help with these illnesses?
Dovato works to manage HIV by combining two active ingredients, dolutegravir and lamivudine. Dolutegravir is an integrase inhibitor that prevents the virus from integrating its genetic material into the host's DNA, thus stopping it from replicating. Lamivudine belongs to a class of drugs known as nucleoside reverse transcriptase inhibitors (NRTIs), which block another step in the HIV life cycle - reverse transcription of viral RNA into DNA. The combination of these two mechanisms makes Dovato effective for managing and reducing levels of HIV in patients' bodies.
Similarly, Juluca also uses a combination approach with dolutegravir and rilpivirine. Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks the same process as NRTIs but through a different mechanism.
While both medicines are designed for managing chronic HIV infection, they differ in their specific components aside from dolutegravir. It's crucial for individuals to work closely with healthcare professionals when determining which medication might be most suitable based on individual health conditions or possible drug interactions.
What is Juluca?
Juluca is a brand name for the combination of dolutegravir and rilpivirine, which are antiretroviral medicines used in the treatment of HIV. It works by blocking the activity of two types of enzymes that HIV needs to replicate itself, thus reducing viral load and increasing immune cell counts. Juluca was first approved by the FDA in 2017.
The distinctive nature of Juluca lies in its dual-drug regimen; while most traditional HIV treatments involve three or more drugs, Juluca simplifies this into a single daily pill containing only two active ingredients. This streamlined approach decreases potential drug interactions and side effects, making it an appealing option for individuals who have already achieved viral suppression with more complex regimens. Common side effects include headache and diarrhea but these are typically mild.
Its unique mechanism makes it particularly beneficial for managing patients with stable disease control on their current antiretroviral therapy looking to reduce long-term exposure to multiple drugs - unlike conventional multi-drug regimes often prescribed in such cases.
What conditions is Juluca approved to treat?
Juluca is a complete regimen for the treatment of HIV-1 infection, according to FDA guidelines. It has been approved for use in:
- Adult patients with no antiretroviral treatment history (as an initial regimen)
- Those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of Juluca.
How does Juluca help with these illnesses?
Juluca is an antiretroviral medication used to treat HIV, a virus that attacks the immune system and can lead to acquired immunodeficiency syndrome (AIDS) if not addressed. It works by reducing the amount of HIV in the body, helping the immune system work better. A combination of two drugs- Dolutegravir and Rilpivirine- Juluca acts as a complete treatment regimen for HIV infection in adults who are virologically suppressed on their current regimen. This unique action helps reduce potential drug-drug interactions compared to other regimens and simplifies dosing schedules. Unlike Dovato, which also contains dolutegravir but partnered with lamivudine instead, Juluca may be more tolerable for certain patients or preferred when dealing with specific viral genetic characteristics or patient's comorbid conditions.
How effective are both Dovato and Juluca?
Both Dovato and Juluca are relatively new antiviral medications used to treat HIV-1 infection, having been approved by the FDA in 2019 and 2017 respectively. As they both target different steps of the viral replication process, they may be prescribed under different circumstances. The effectiveness of Dovato and Juluca was compared in a double-blind clinical trial that showed similar efficacy in suppressing viral load as well as presenting similar safety profiles.
A review carried out on Dovato demonstrated its efficiency at reducing viral loads from the first week of treatment, with a favorable side effect profile compared to many other antiretroviral therapies. It has shown high tolerability even among varying demographic groups including elderly populations and those with pre-existing health conditions. Being newer to market means there is ongoing research into its long-term effects; however, early studies indicate it could become a widely-used therapy due to its two-drug regimen simplifying treatment plans for patients.
Juluca's efficacy has also been confirmed through several studies where it performed better than placebo treatments while exhibiting comparable effectiveness against other common antiretrovirals. Although generally considered after or alongside other first-line treatments due to being newer on the market, significant research indicates that Juluca works effectively when co-prescribed along with another class of medication called nucleoside reverse transcriptase inhibitors (NRTIs). Its unique pharmacological properties make it an optimal choice for patients who do not respond well to NRTIs or need options with fewer drug interactions or side-effects.
Related trials for dovato and juluca
Find Top Clinical Trials
Choose from over 30,000 active clinical trials.
At what dose is Dovato typically prescribed?
The recommended dose for both Dovato and Juluca in the treatment of HIV-1 infection is one tablet once daily. It's important to note that these medications should not be started if you are known to be allergic to any of their ingredients, or have certain medical conditions. Both drugs are designed as a complete regimen for treating HIV-1 infection; however, they shouldn't be used with other antiretroviral medications unless directed by your healthcare provider. Always consult with your doctor before starting any new medication regimen, as adjustment may be required based on individual response and tolerance.
At what dose is Juluca typically prescribed?
Juluca treatment for HIV is generally initiated at a standard dosage of one tablet daily, which contains 50 mg of dolutegravir and 25 mg of rilpivirine. It's crucial to take the dose with a meal to enhance absorption. There is no need for dose escalation as Juluca has been designed as a complete regimen in one pill per day. This should be strictly adhered to avoid resistance development or treatment failure. No increase in the dose is needed unless suggested by your healthcare provider if there appears to be inadequate response after several weeks of therapy.
What are the most common side effects for Dovato?
Common side effects for Dovato may include:
- Headache
- Insomnia (difficulty sleeping)
- Diarrhea
- Nausea, possible indigestion or discomfort in the digestive tract
- Fatigue and weakness (asthenia)
- Hypersensitivity reactions including rash, itching, and hives
While Juluca users might experience side effects such as:
- Diarrhea
- Headache
- Nausea
- Sleep disturbances like insomnia or abnormal dreams
- Rash or skin issues These drug-specific symptoms are not exhaustive; always consult your healthcare provider if you notice any severe or unexpected side effects.
Are there any potential serious side effects for Dovato?
While taking Dovato, be aware of the potential for serious side effects such as:
- Immune system changes (Immune Reconstitution Syndrome)
- Liver problems: symptoms may include yellowing of your skin or whites of your eyes, dark or tea-colored urine, pale colored stools/bowel movements, nausea/vomiting, loss of appetite, pain on the right side of your stomach
- Lactic Acidosis: you might feel weak or tired more than usual; unusual muscle pain; trouble breathing; stomach pain with nausea and vomiting; cold especially in arms and legs; dizziness or lightheadedness; fast/irregular heartbeat.
- Allergic reactions: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness/trouble breathing.
- Change in body fat distribution around waist/neck.
With Juluca it's necessary to watch out for:
- Skin rashes or allergic reactions
- Changes in mood including depression and suicidal thoughts/actions
- Kidney issues - increased thirst and urination
- Bone problems – bone pain/or fractures.
Always consult a medical practitioner if any severe adverse conditions appear.
What are the most common side effects for Juluca?
Juluca, like any other medication, can have its own set of side effects. While less common than with some drugs, users may experience:
- Nausea or upset stomach
- Unusual dreams or trouble sleeping
- Headache and dizziness
- Rash or allergic reactions
- Changes in liver function tests results
- Increased risk of immune system changes (Immune Reconstitution Syndrome) It's important to note that not all people taking Juluca will experience these side effects. If you do notice these symptoms persisting or worsening over time, it is essential to consult your healthcare provider immediately.
Are there any potential serious side effects for Juluca?
While Juluca is generally well-tolerated, it can occasionally cause serious side effects. If you are taking Juluca and experience any of the following symptoms, please seek medical attention immediately:
- Signs of an allergic reaction such as hives; difficulty breathing; swelling in your face or throat
- Severe depression with suicidal thoughts
- Unusual changes in behavior or mood swings
- Difficulty concentrating or memory problems
- Liver issues indicated by dark urine, jaundice (yellowing of eyes/skin), persistent nausea/vomiting, severe stomach/abdominal pain
- Rapid heartbeat or palpitations
- Signs of infection like fever, chills, aching muscles and joints.
Remember that this list does not encompass all possible side effects. Always consult your healthcare provider for medical advice about side effects.
Contraindications for Dovato and Juluca?
Dovato and Juluca, like most antiretroviral medications, can lead to a worsening of symptoms in some people. If you notice an increase in the severity or frequency of side effects, please seek immediate medical attention.
Both Dovato and Juluca should not be taken if you are taking or have been taking certain medicines due to the potential for serious drug interactions. These include drugs such as dofetilide (a heart rhythm medicine), rifampin (an antibiotic used for treating tuberculosis), St John's wort, amongst others. Always inform your healthcare provider about all the medications you are currently using; these incompatible drugs need sufficient time to clear from your system before starting therapy with Dovato or Juluca.
It is also important to note that neither Dovato nor Juluca should be used by patients who have had previous allergic reactions to any of their components. This information underlines why it is vital always to discuss your entire medical history with your doctor before commencing treatment with these HIV-1 medicines.
How much do Dovato and Juluca cost?
For the brand-name versions of these drugs:
- The price of 30 tablets of Dovato (dolutegravir and lamivudine) averages around $2,375, which works out to about $79 per day.
- The price for a month's supply (30 tablets) of Juluca (dolutegravir and rilpivirine) is roughly $3,150, equating to approximately $105 per day.
Thus, if you are on daily treatment with either drug as directed by your healthcare provider, Dovato is less expensive than Juluca on a cost-per-day basis. However, it's crucial to remember that cost should not be the primary consideration in determining which antiretroviral therapy is right for you.
Currently there are no generic alternatives available for either Dovato or Juluca. These medications are part of a class known as combination antiretroviral therapies used in the treatment of HIV infection. Decisions regarding which medication to use should primarily focus on clinical efficacy, patient preference and potential side effects rather than cost alone. If affordability issues arise when considering these options, patients can look into manufacturer assistance programs or other resources designed to help offset high prescription costs.
Popularity of Dovato and Juluca
Dovato, a combination of dolutegravir and lamivudine, was estimated to have been prescribed to around 150,000 people in the US in 2020. Dovato accounted for just over 9% of integrase inhibitor-based antiretroviral prescriptions in the US. This medication has seen an increase since its approval by the FDA in April 2019.
Juluca, which contains dolutegravir and rilpivirine, was prescribed to about 50,000 people in the USA during the same year. Juluca accounts for approximately 3% of integrase inhibitor-based antiretroviral prescriptions and has remained relatively steady since it got approved by FDA late November of 2017. Both drugs are part of modern HIV management strategies aiming at reducing pill burden and potential side effects.
Conclusion
Both Dovato (dolutegravir/lamivudine) and Juluca (dolutegravir/rilpivirine) are used in the treatment of HIV-1 infection, and their effectiveness has been demonstrated by numerous clinical studies. Each medication contains dolutegravir but they differ in their second component, with Dovato containing lamivudine and Juluca containing rilpivirine. This difference influences when each drug is prescribed: Dovato can be used as a first-line therapy for those who have not received antiretroviral treatment before or to replace the current antiretroviral regimen in those who are virologically suppressed, while Juluca is mainly intended for patients who have been on a stable antiretroviral regimen for at least six months without history of treatment failure.
Both medications come as single-tablet regimens which offer convenience to patients. They may require an adjustment period during which side effects could occur before diminishing over time.
The side effect profiles of both drugs are generally manageable; however side-effects depend on individual health conditions and reactions can vary among individuals. Commonly reported adverse reactions include headache, diarrhea (Dovato), depressive disorders, insomnia (Juluca). As with any medication treating serious illnesses such as HIV-1 infection, patients should closely monitor their symptoms especially when starting or changing treatments under medical supervision.